351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (833)
- Autoimmune Disorders (1)
- Blood Disorders (4)
- Cancer
(726)
- Bladder Cancer (14)
- Brain Cancer (25)
- Breast Cancer (70)
- Gastrointestinal (16)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- (-) Leukemia (75)
- Liver Cancer (10)
- Lung Cancer (62)
- Lymphoma (45)
- Multiple Myeloma (30)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- (-) Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- COVID-19 (Coronavirus) (1)
- Diabetes (2)
- Ear, Nose and Throat (1)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (2)
- Healthy Volunteers (8)
- Liver Disease (1)
- Neurological Disorders (31)
- Obesity (1)
- Obstetrics & Gynecology (6)
- Pediatrics (42)
- Psychiatric Disorders (1)
- Surgery (1)
- Transplant (3)
- Urology (1)
Displaying 1 - 100 of 100
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The study involves research of two study drugs (TSC 100 and TSC 101), given in combination with the standard of care (SOC). The purpose of the study is to see if TSC 100 and TSC 101 are safe and effective in treating your blood cancer. The study also is measuring the effect of these study drugs on your immune system (…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drugs, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer are testing to see if SEA-CD70 is safe…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (investigational) …
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The experimental drug called INBRX 109 has been developed as a treatment for unresectable or metastatic conventional chondrosarcoma. The purpose of this study is to learn about the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective…
Condition: Cancer / Sarcoma
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The main goal of this study is to find out about how duvelisib acts in patients with CLL/SLL who were previously treated with a BTKi (Bruton Tyrosine Kinase inhibitor - commercially available ibrutinib or another investigational BTKi). Duvelisib is an investigational drug, meaning that it is not FDA approved, designed to try to stop…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this part of the study is to obtain further information about the safety and effectiveness(how well it works) of azacitidine plus birinapant (the investigational drug), in people with higher-risk myelodysplastic syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMMoL). One of the standard drugs for these diseases is azacitidine which all…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to test the good and bad effects of the drugs called belinostat and SGI-110 (guadecitabine). These drugs could shrink your cancer, but they could also cause side effects. The study doctors hope to learn if the study drugs will shrink the cancer more often than…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR20A to treat certain types of cancers. PBCAR20A is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you,…
Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Currently Recruiting
This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone,…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
This research study mainly aims to test the safety and tolerability of AGEN1181 and balstilimab and to determine the most appropriate dose of the study drug AGEN1181 alone and in combination with balstilimab. AGEN1181 targets cells that are a part of the body's immune system to block a protein called cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed, or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The study drug, CFT8634, is an investigational therapy that has been shown in animal studies to help break down the BRD9 protein, an important protein in the body that helps SMARCB-null tumors, such as your own, to grow. CFT8634 is able to do so by using the body's own protein-recycling equipment. (In short, your cells are capable of breaking down proteins…
Condition: Cancer / Sarcoma
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerated dose of the study drug will be determined. In the phase II portion,…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a blood cancer called Acute Myeloid Leukemia (AML) with or suspected to have a specific gene mutation (TP53 mutation) for which you have not received any prior AML treatment. Tumor protein p53 (TP53) is a gene that codes for a tumor…
Condition: Cancer / Sarcoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This research study is evaluating an investigational drug, called cirmtuzumab, in combination with astandard drug, called ibrutinib (Imbruvica), as a possible treatment for patients with CLL/SLL or MCL. All cells in the body receive signals to grow and survive, but sometimes these signals get out of control, causing too much cell growth. When the growth of…
Condition: Cancer / Leukemia
Investigator: Alice Lee, MD
Status: Closed
This study is for children and teens who have been diagnosed with Acute Myeloid Leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to establish the safety profile of the study drug HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. HuMax-AXL-ADC binds to a specific antigen called Axl, which is expressed on the tumor cells in the cancer types treated in this trial. When the trial drug binds to the…
Study of sertraline (Zoloft) with ara-C in combination in patients with acute myeloid leukemia (AML)
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of the study is to evaluate the safety, tolerability (the effect of the drug on your body), pharmacokinetics (the effect of your body on the drug) and maximum tolerated dose of sertraline in combination with cytosine arabinoside (ara-C, cytarabine) when given to patients with treatment-resistant myeloid leukemia. In addition, the effect of the…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Closed
The purpose of this study is to find out if the drugs called Nivolumab and 5-Azacytidine can be given safely in children and young adults with Acute Myeloid Leukemia (AML) which has come back after treatment or has not responded to standard therapy. These drugs are thought to work by turning on genes that limit the growth of cancer…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated,…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to determine the effectiveness of the study treatment- bendamustine and rituximab (BR) followed by venetoclax for 12 months. The combination of the drugs bendamustine and rituximab is a commonly used treatment for your disease. Venetoclax is an oral drug that blocks a protein called BCL-2 which is present on CLL cells. With this…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness, and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
Patients who will be receiving immune effector cell (IEC) therapy for the treatment of their cancer (leukemia) are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Syndrome (CRS). CRS involves a release of a large amount of proteins into the bloodstream. This may cause…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease.…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with soft tissue sarcoma (STS) prior to surgery. The AMG 232 is investigational. It has been tested in other cancers but not yet in sarcoma. AMG 232 has not been tested using the dosing schedule in this study and it…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to find if PTC299 is safe to treat people with relapsed/refractory acute myeloid leukemia (AML) as well to determine the dose of PTC299 that can be given without causing severe side effects. AML is a cancer of the blood and bone marrow (spongy tissue inside bones where blood cells are made).…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine if the study drug toripalimab is safe, to determine future doses to give to patients with cancer, and to measure the amount of toripalimab in the blood. Up to approximately 240 subjects will be enrolled in Part B. The dose given in Part B will be 240 mg. The dose was chosen based upon…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study is for patients with Richter's transformation (RT). The purpose of this study is to see if a new type of investigational drug called PNT2258 that may be effective in blocking the "on" signal to cancer cells, eventually causing them to die. We are trying to see if PNT2258 provides evidence of anti-tumor effect by…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The researchers hope to study the effectiveness of an investigational drug called AL3818 in people who have metastatic (meaning their disease has spread) or advanced ), specifically alveolar soft partsarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS). The main purpose of the study isto learn the percentage of patients that respond to treatment…
Condition: Cancer / Leukemia
Investigator: Todd Rosenblat, MD
Status: Closed
The purpose of the study is to test how effective and safe the study drug SGI-110 is compared with current standard treatment for AML. The study drug, SGI-110, is changed in the body into a compound called decitabine. Decitabine is an approved drug in the US for treatment of patients with myelodysplastic syndrome (MDS) and in Europe for treatment of…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to investigate if a drug called Vedolizumab is safe and effective in preventing acute graft-versus-host disease (attack of donor cells on recipient healthy organs after transplant) of the gut in comparison to placebo (dummy drug). This will be studied in patients undergoing Allogeneic Hematopoietic Stem Cell…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to evaluate how well the study drug ABT-199 works and safety of ABT-199 in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back (relapsed) after treatment or no response (refractory) to treatment with B-cell receptor signaling pathway inhibitor therapy, namely Ibrutinib and/…
Condition: Cancer / Leukemia
Investigator: Todd Rosenblat, MD
Status: Closed
The goal of this research study is to find the safest highest dose of SL-401 that can be given to patients with AML or BPDCN. This study will also look at how SL-401 stops or slows leukemia or BPDCN growth and how SL-401 enters and leaves the body. This study will also look at certain proteins in the blood and bone marrow and how the amounts of them might…
Condition: Cancer / Leukemia
Investigator: Markus Mapara, MD
Status: Closed
The purpose of the study is to learn if a transplant using bone marrow recovered from deceased organ and tissue donors is safe and effective in patients undergoing bone marrow transplant (BMT). This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard of care for transplant. Bone marrow cells…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
You are being asked to participate in this study because you have acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or leukemia of mixed lineage (the leukemia cells cannot be classified as AML or ALL or where both types of AML and ALL cells are present). Because you have already received standard therapy that is no longer helping, or there is…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study will be performed to determine if Panzyga (the study drug) can help with preventing infections in patients who have chronic lymphocytic leukemia (CLL). Panzyga is a study drug administered via injection into the vein, which contains human antibodies also called immunoglobulins. It is manufactured by Octapharma. Your participation in this clinical…
Condition: Cancer / Leukemia
Investigator: Markus Mapara, MD
Status: Closed
You are being asked to take part in this study because you have acute myeloid leukemia (AML). Vor Biopharma, is a company that is testing a possible new treatment for AML. This possible new treatment, is VOR33. In this study, your blood-forming stem cells will be genetically modified to become VOR33. VOR33 has not been approved by the Food and Drug…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to evaluate the effects of etavopivat, good and bad, in individuals with myelodysplastic syndrome (MDS).
Condition: Cancer / Leukemia
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to find the best dose of Quizartinib that can be given safely with chemotherapy in children and young adults with acute myeloid leukemia (AML) which has come back or has not responded to the standard therapy. Quizartinib will be given by mouth once a day from Day 6 through Day 28. It will be given in combination with…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of an investigational treatment called pirtobrutinib (LOXO-305) plus venetoclax and rituximab (PVR) versus venetoclax and rituximab (VR). Pirtobrutinib is an investigational (or experimental) drug that may treat your Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to find out whether people who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD- negative) when they stop treatment.
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to evaluate the safety and efficacy of venetoclax and azacitidine compared to Best Supportive Care in patients with Acute Myeloid Leukemia (AML) after an allogeneic stem cell transplant (SCT). This is the first randomized study comparing venetoclax in combination with azacitidine versus best supportive care in subjects with AML…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
You are being asked to participate in this study because you have a myeloproliferative neoplasm (MPN) that has transformed to accelerated or blast phase. MPN is a group of diseases in which the bone marrow makes too many blood cells. The different types of MPN are myelofibrosis (MF), essential thrombocythemia (ET), or polycythemia vera (PV). Over time,…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to learn about the safety, tolerability, and effectiveness of an investigational drug called milademetan as compared to the use of trabectedin. In this study, subjects will be randomly assigned (like flipping a coin) to receive one of two study drugs: milademetan or trabectedin. This is an open-label study, meaning you will know…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of the study is to determine an appropriate dose of KRT-232 in combination TL-895 or KRT-232 alone for treatment of myelofibrosis (MF). There are 2 parts planned for this study, the Phase 1b that will test different doses of TL-895 given with KRT-232 and it will also test KRT-232 alone, to identify the recommended dose for Phase 2. The Phase 2 (…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to determine the optimal dose of oral CGT9486 in patients with Advanced Systemic Mastocytosis (AdvSM) and to determine the efficacy of CGT9486 at the selected optimal dose in patients with Advanced Systemic Mastocytosis (AdvSM). This includes Aggressive Systemic Mastocytosis, Advanced Systemic Mastocytosis with an Associated…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to compare the effects, both good and bad, of magrolimab in combination with azacitidine, to those of azacitidine in combination with placebo, to find out which is better for treating patients with MDS (Myelodysplastic Syndrome). Other purposes of this study include determining the quantity of magrolimab in the blood, aspects of…
Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Closed
The purpose of this study is to assess the safety, effectiveness, pharmacokinetic (PK how long the drug is in your body and how it is metabolized) and pharmacodynamics (PD where does the drug go in your body and what is its biological effect) of the study drug, GFH009, in patients with relapsed or refractory hematologic malignancies including acute myeloid…
A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma, a type of soft tissue sarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find out what dose of pacritinib is safest and works best for participants. Pacritinib is an experimental drug, which is a drug that is being tested and is not currently approved by the Food and Drug Administration (FDA) in the US. The study will be conducted at about 85 study clinics in North America, Europe, Israel and…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to: Test if the lifespan of study participants is increased when uproleselan is added to standard chemotherapy medicines compared to standard chemotherapy alone; test if the number of study participants achieving disease remission is increased when uproleselan is added to standard chemotherapy medicines compared to standard…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. (A doseis a measured amount of a drug taken at one time.) The effects of imetelstat on myelofibrosis as well as any side effects will be explored.
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to learn about the effects, safety, and proper dosage of tazemetostat in combination with doxorubicin for the treatment of soft tissue sarcoma. Doxorubicin is a common therapy for soft tissue sarcoma, but is not FDA approved in combination with tazemetostat. This study treatment combination may suppress or prevent tumor growth…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The main purpose of this study is to see how effective an investigational new drug (tipifarnib, the study drug) is to treat myelodysplastic syndrome (MDS). "Investigational" means that tipifarnib has not yet been approved by regulatory authorities such as the United States Food and Drug Administration (FDA) for use outside of clinical trials. You…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The main purposes of this study are to: 1) understand the safety of atezolizumab given in combination with Hu5F9-G4 and 2) understand the way the body processes atezolizumab and Hu5F9-G4 (pharmacokinetics). This study will also be testing if the combination therapy is effective at treating relapsed or refractory acute myeloid leukemia (R/R AML).…
Condition: Cancer / Leukemia
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with Acute Myeloid Leukemia (AML). The purpose of this study is to determine if decitabine plus JNJ-56022473 can be safely combined and is active for your disease. The study drugs used in this study are JNJ-56022473, an experimental drug and DACOGEN ( also known generic as decitabine), a drug already used to treat your type of…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to determine how well a drug called rigosertib works on people with MDS and to study the safety of rigosertib when it is given to people with MDS. Rigosertib is currently being tested in other clinical research studies.
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study, which involves research, is to determine if an experimental drug: acalabrutinib is safe and effective in the treatment of this patients with High Risk Chronic Lymphocytic Leukemia (CLL). Acalabrutinib is an investigational drug, which means that it is still being tested in people and has not been approved by government agencies in…
Condition: Cancer / Leukemia
Investigator: Monica Bhatia, MD
Status: Closed
The purpose of this study is to compare two different combinations of treatment plans to a standard transplant procedure in order to see whether one or both of them are better at reducing the occurrence and severity of chronic GVHD. The research portion of this study involves manipulation of your stem cell product by removing T-cells, which cause chronic…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of the study is to see if a medicine called gilteritinib/ASP2215 given in combination with atezolizumab is both effective and safe as a treatment for AML patients with mutations in the FLT3 gene. Some AML patients have a mutation in the gene called FLT3. When patients have a FLT3 mutation, more of the FLT3 protein is on the leukemic cells, or…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of the study is to see if a medicine called ASP2215 is both effective and safe as atreatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3Mutation Assay companion diagnostic (a specific way to test your blood or bone marrow, which is used to see if you have a mutation of the FLT3 gene), compared to salvage…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this study is to evaluate the efficacy (how well the study drug works) and safety of venetoclax in combination with azacitidine in subjects who have not been treated for their acute myeloid leukemia (AML). The tolerability (the degree to which evident adverse effects can be tolerated by the patient) of venetoclax will also be evaluated.
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this research study is to determine the preliminary safety and effectiveness (how well something works) of alvocidib when used after the standard drug decitabine in patients with MDS. The study will also gain information about the PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body),…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of preoperative radiation therapy used in combination with the immunostimulatory agent talimogene laherparepvec (T-VEC) to improve outcomes for patients with resectable soft tissue sarcomas, including soft tissue sarcoma (liposarcoma (excluding myxoid liposarcoma), leiomyosarcoma and…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of avapritinib (also known as BLU-285) in individuals who have been diagnosed with aggressive systemic mastocytosis (ASM), Systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell Leukemia (MCL). Avapritinib is an experimental drug means that is is not yet known if…
Condition: Cancer / Leukemia
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to find the best dose of pevonedistat that can be given safely with chemotherapy in young adults with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) that has either come back or has not responded to the standard therapy. Pevonedistat works by blocking some of the enzymes that are needed for cell growth.
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of the study is to see if a combination of idelalisib and BI 836826 can help control patients with Chronic Lymphocytic Leukemia (CLL) without serious side effects.
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of a new combination treatment involving two drugs: selinexor and ixazomib, for the treatment of dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. The primary objective of the study is to determine the maximum tolerated…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
This is a clinical research study for subjects with Acute Myeloid Leukemia (AML) who have not received any treatment for their disease and who are over the age of 60. These patients will be treated with low-does cytarabine in combination with Lintuzumab-Ac225. Low dose cytarabine has been investigated in elderly AML patients for at least two decades and is…
Determining Changing in Cardiovascular and Metabolic Risks in Patients with Chronic Myeloid Leukemia
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
This study will see how the treatment you will receive for your chronic myeloid leukemia affects cardiovascular and metabolic risk factors. The treatments that are being studied are called BCR-ABL1 tyrosine kinase inhibitors (TKIs) (i.e., dasatinib, imatinib, nilotinib). Subjects who are eligible for the study will be starting treatment for chronic myeloid…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to provide samples for biomarker testing for the different MPD-RC treatment studies. As part of the treatment study you currently participating in, this is an additional research study in which you we will ask for you to donate blood and/or bone marrow samples, two nail clippings, and buccal (cheek) swab. In order to…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The overall purpose of this part of the study is to determine the best dose of JCAR017 for treating adult participants with relapsed or refractory B-cell Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL) and to understand the side effects that participants with your disease may have when they are treated with JCAR017.
Condition: Cancer / Leukemia
Investigator: Azra Raza, MD
Status: Closed
The purpose of the study is to evaluate the efficacy and safety of imetelstat for the treatment of patients with myelodysplastic syndrome (MDS). All patients participating in Part 1 of this study will get 7.5 mg/kg of imetelstat as a 2-hour intravenous infusion once every 4 weeks. The dose of imetelstat may be increased, held or decreased depending on how…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
This is a clinical research study for subjects with Myelofibrosis (Primary, Post-Polycythemia Vera, and Post-Essential Thrombocytopenia) and thrombocytopenia. The purpose of this study is to determine if pacritinib is better at reducing spleen size and a reduction in symptoms than the best available therapy. This is a randomized, controlled study.…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
You are being asked to take part in this study because you have acute myeloid leukemia (AML) that has come back after initial treatment (relapsed) with venetoclax combination therapy or because you did not get a complete response from your initial treatment (refractory) with venetoclax combination therapy. The purpose of this research study is to determine…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety of the combination of the experimental drugs called atezolizumab and guadecitabine (not yet approved by the U.S. Food and Drug Administration FDA or any other regulatory authority outside the United States) to find out what effects, good or bad, the combination of atezolizumab and guadecitabine has on patients…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
We are doing this study to find out if an investigational drug called CPI-0610 can help with myelofibrosis. An investigational drug is a drug that is not approved for sale in the United States by the Food and Drug Administration (FDA). This study has two groups (arms) one group of patients will be treated with CPI-0610 alone (monotherapy arm) and the other…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study, which involves research, is to determine if giving an experimental drug called acalabrutinib in combination with venetoclax with and without obinutuzumab is safe and effective for treating people with CLL compared to a combination of bendamustine and rituximab (BR) or a combination of Fludarabine, Cyclophosphamide and Rituximab (…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to see if a medicine called ASP2215 is both safe and effective as atreatment for patients with Acute Myeloid Leukemia (AML). ASP2215 is an experimental drug that is being studied to treat AML. In this study, ASP2215 will be given in addition to a standard chemotherapy regimen that patients could be receiving even if they were…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents in treating patients with chronic lymphocytic leukemia (CLL).
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to determine if oral azacitidine (CC-486) is safe and effective as maintenance therapy in continuing the response patients had with their last acute myeloid leukemia (AML) treatment and improving the quality of that response. Currently, there is no standard treatment to maintain or improve patient response and patients are…
Condition: Cancer / Leukemia
Investigator: Mark Frattini, MD, PhD
Status: Closed
Pevonedistat is currently being studied in humans with advanced solid tumors and acute myelogenous leukemia (AML). The current study is designed to evaluate pevonedistat in combination with azacitidine in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and low-blast AML. This study will assess whether taking…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety of DCLL9718S at different dose levels, alone or in combination with azacitidine. DCLL9718S is an experimental drug manufactured by Genentech that is designed to inhibit tumor growth. The drug is being tested in clinical trials and has not been approved by the U.S. Food and Drug Administration (FDA) and/or any…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to evaluate the safety, and effectiveness of ABT-199 in combination with decitabine and ABT-199 in combination with azacitidine in subjects who have not been treated for their AML. In addition, substances (biomarkers) found in the blood and bone marrow that may indicate the effects or progress of the leukemia and the activity of…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this research study is to determine the effectiveness (how well something works) and safety of an investigational compound called alvocidib when used in a combination chemotherapy therapy regimen in patients with acute myeloid leukemia (AML) who test positive for NOXA priming.
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this study is to measure the effectiveness and safety of an investigational drug called "alovicidib" in combination with cytarabine and daunorubicin in the treatment of AML. Investigational means that this drug has not been approved by the FDA. Cytarabine and daunorubicin are both standard of care treatments for patients with AML.…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this research study is to find out if the study drug MBG453 in combination with other drugs (decitabine or azacitidine) already commonly used to treat MDS is safe and has beneficial effects in people who have some types of MDS like you (intermediate, high, or very high risk MDS). Subjects will be administered the study treatment as indicated…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this research study is to learn more about adding the drug ADI-PEG 20 to a standard treatment regimen called gem-tax (the chemotherapy drugs gemcitabine and docetaxel) for subjects with bone and soft tissue sarcoma, and how the addition of ADI-PEG 20 affects the tumors response to treatment and the side effects you experience.
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to compare the safety, tolerability, and effectiveness of ruxolitinib, an investigational drug, compared to anagrelide, an FDA approved drug. Investigational means that the study drug has not been approved by the FDA for treatment of ET. Patients will be assigned to one of two groups. Group A will receive ruxolitinib and placebo…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of an experimental medication, FT-2102, in the treatment of acute myeloid leukemia or myelodysplastic syndrome. Patients will receive either FT-2102 alone or in combination with cytarabine or azacitidine, an approved drug commonly used in the treatment of AML and MDS. Subjects will remain on…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of the study drug nirogacestat for the treatment of desmoid tumors/aggressive fibromatosis (DT/AF). One group will receive the study medication, the other group will receive a placebo. After the initial phase of the study, participants may elect to participate in another phase of the…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
You are being asked to take part in this study because you have been diagnosed with Myeloproliferative neoplasm (MPN) Associated Myelofibrosis (your disease) and have received ruxolitinib. The purpose of this study is to confirm how well this study treatment works to reduce your spleen volume, spleen size, what effect the study treatment has on you and…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE